Eli Lilly and Company (FRA:LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 778.92B |
| Revenue (ttm) | 50.64B |
| Net Income (ttm) | 15.69B |
| Shares Out | n/a |
| EPS (ttm) | 17.42 |
| PE Ratio | 49.64 |
| Forward PE | 32.13 |
| Dividend | 5.35 (0.61%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | 132 |
| Average Volume | 469 |
| Open | 869.70 |
| Previous Close | 868.90 |
| Day's Range | 869.70 - 875.90 |
| 52-Week Range | 537.40 - 967.00 |
| Beta | n/a |
| RSI | 51.76 |
| Earnings Date | Feb 6, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
With Netflix's 10-for-1 Stock Split Complete, Here Are 3 Growth Stocks to Buy in December That Could Issue Stock Splits in 2026
Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new year.
Dow Jones Futures: Small Caps Surge, Eli Lilly Faces Test; 5 Stocks In Buy Zones
Small caps nearly hit all-time highs as the major indexes paused. Eli Lilly is at a key level while Robinhood led new buys. Ulta Beauty led earnings late.
Behind the Scenes of Eli Lilly's Latest Options Trends
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly . Looking at options history for Eli Lilly (NYSE: LLY) we detected 28 trades. If we consider the specifics of e...
Eli Lilly (LLY): BMO Capital Raises Price Target, Maintains Rating | LLY Stock News
Eli Lilly (LLY): BMO Capital Raises Price Target, Maintains Rating | LLY Stock News
Chinese Biotech Ming Yu Well Positioned For A Strong Hong Kong IPO
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways: The company has a pipelin...
Eli Lilly And Indiana University Sign $40 Mln Agreement To Expand Clinical Trials In Indiana
(RTTNews) - Eli Lilly and Company (LLY) announced that it has entered into a new agreement with Indiana University (IU) to provide up to $40 million aimed at expanding access to clinical trials across...
FDA Expands Approval For Lilly's Cancer Drug Jaypirca
(RTTNews) - Eli Lilly and Co. (LLY) announced that the FDA has expanded cancer med Jaypirca's approval to include treatment for adults with relapsed or refractory chronic lymphocytic leukemia or small...
FDA Grants Full Approval To Eli Lilly's Jaypirca For CLL/SLL
(RTTNews) - Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100 mg and 50 mg tablets) for the treatment of adult patients with ...
Companies Cut Prices For Blockbuster Weight-Loss Drugs
In this week's edition of InnovationRx, we look at the price cuts for blockbuster weight-loss drugs, the Forbes 30 Under 30 Healthcare list, the coming barriers to getting vaccines, and more. To get i...
Eli Lilly (LLY) Gains FDA Approval for Expanded Use of Jaypirca
Eli Lilly (LLY) Gains FDA Approval for Expanded Use of Jaypirca
Eli Lilly (LLY) Secures FDA Approval for Pirtobrutinib in Leukemia Treatment
Eli Lilly (LLY) Secures FDA Approval for Pirtobrutinib in Leukemia Treatment
1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year
A key catalyst may be right around the corner.
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded indica...
GXP-Storage Appoints Former Eli Lilly Global Clinical Research Executive Chris Otto to Board of Directors
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Chris Otto brings over three decades of global clinical research experience to the Board of Directors of GXP-Storage.
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.
Eli Lilly (LLY) Pauses UK Investments Amidst Awaited Drug Approval Changes
Eli Lilly (LLY) Pauses UK Investments Amidst Awaited Drug Approval Changes
2 Trillion-Dollar Dividend Stocks to Buy and Hold for 10 Years
These two market leaders boast significant growth prospects in their niches. They increased their payouts at a good clip over the past decade.
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Howard University Receives $10M Gift from Lilly Endowment to Support Efforts to Advance Over 155 Years of Black Theological Education
Washington, D.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Howard University has received a grant of $10 million from Lilly Endowment Inc. through its Pathways for Tomorrow Initiative. The funding will help ...
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple
After a rough pullback, the major indices are attempting to rebound higher.Helping, not only is Bitcoin starting to rebound, but so are down but not out tech stocks. Plus, markets are optimistic that ...
BA Flies on Strong Commentary, WDC & STX Price Target Hikes, LLY Boost
Boeing (BA) opened Tuesday's trading action as the stronger performer in the SPX. Diane King Hall points to commentary from the company on returning to positive free cash flow lifting the plane manufa...
Here are Tuesday's biggest analyst calls: Nvidia, Apple, AMD, Micron, Amazon, Eli Lilly, Cloudflare & more
Here are Tuesday's biggest calls on Wall Street.
Bank of America hikes Eli Lilly price target on promising drug pipeline
Bank of America's new price target has shares of Eli Lilly climbing 22% from here.